Login to Your Account



Clinic Roundup


Tuesday, March 20, 2012
• Genmab A/S, of Copenhagen, Denmark, submitted a protocol amendment for its ofatumumab Phase III head-to-head study in diffuse large B-cell lymphoma (DLBCL). Patients in the study will receive ofatumumab plus chemotherapy or Rituxan (rituximab, Biogen Idec Inc. and Roche AG) plus chemotherapy.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription